This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Market Timing Secrets No One Talks About - October 14, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Adverum Biotechnologies Enters Oversold Territory
by Zacks Equity Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Keys to Successfully Timing the Markets - September 24, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
by Zacks Equity Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
The Keys to Successfully Timing the Markets - September 04, 2019
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
The Keys to Successful Timing the Markets - August 15, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 25.81% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Self Care Americas segment. It remains to be seen if this benefits the company's results in the soon-to-be reported quarter.
Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Adverum (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.
What Makes Adverum Biotechnologies (ADVM) a New Strong Buy Stock
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adverum (ADVM) Jumps: Stock Rises 5.1%
by Zacks Equity Research
Adverum (ADVM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Adverum Biotechnologies, Inc. (ADVM).
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
by Zacks Equity Research
Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 17.86% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.